Please find attached Sanofi response to the European Commission Public Consultation on Public Procurement Rules Revision About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving peoples lives and delivering compelling growth.
SAN
Sanofi
Company · France · EU Transparency Register 61291462764-77
7
positions filed
in the 326 files tracked
5
legislative files
of 326 tracked
5
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 326 consultation files tracked so far (29,503 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 925 companies & groups on this site, they rank #127 by legislative files engaged — a count of participation, not a measure of influence.
2.5
declared lobbying FTE
self-declared
€1.5M+
declared costs / yr (floor)
4
EP accreditations
as declared to the register
2009
in the register since
Declares membership of
- Professional associations:
- AFEP (French Association of Private Companies)
- EFPIA - European Federation of Pharmaceutical Industries and Associations)
- Vaccines Europe →
- EUCOPE
- France Industrie →
- MEDEF →
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026).
- Register category
- Companies & groups
- Registered as
- SANOFI
- Head office
- Paris, France
- EU office
- Brussels
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Sanofi in PolicySpeak: request access →
Work at Sanofi? so we know who speaks for it.
Their record over time
Sanofi filed 7 positions between 11 Jun 2025 and 31 Jul 2026, across 5 of the 326 legislative files tracked here, attaching a full position paper 5 times.
2025 · 2 filed2026 · 5 filed
What they argued
Sanofi Response to the European Commission’s Public Consultation Review of the Technical Criteria of the European Taxonomy (Climate and Environment Delegated Acts) Sanofi welcomes the European Commission’s decision to remove pharmaceutical activities 1.1 Manufacture of active substances and 1.2 Manufacture of medicinal products from the scope of the Pollution objective.
Filed in French · English published by the European Commission
Sanofi has been compliant with the European Taxonomy since 2021. The entry into force of the objective on pollution since the 2023 financial year and the application of the criteria of activity 1.2 Manufacture of medicinal products reveal major obstacles.
Filed in French · English published by the European Commission
Sanofi is one of the world's leading healthcare companies and the largest EU-headquartered pharmaceutical company, with deep and long-standing roots across the European research, clinical development and manufacturing.
Sanofis response to the European Commissions Call for Evidence on EU Biotech Act Sanofi welcomes the European Commission's initiative to develop a European Biotech Act. We believe this represents a critical opportunity to strengthen Europe's position in the global biotech landscape while addressing key challenges facing the sector.
Sanofi welcomes the Commission's Biotech Act II initiative and submits one core message: biopharmaceuticals must be included within the scope of Biotech Act II as a strategic industrial capability. Biomanufacturing is a horizontal industrial capability shared across all end uses. Excluding biopharmaceuticals would leave out the segment where Europe retains its strongest industrial footprint.
Sanofi welcomes the EU Safe Hearts Plan as a timely and much-needed strategic response to Europe's leading public health challenge. We are pleased to contribute to the call for evidence shaping this initiative. Cardiovascular diseases remain the foremost cause of death and disability across the EU.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers — not evidence of coordination, and we do not suggest any.
- Cefic · 4 files in common
- MedTech Europe · 4 files in common
- EFPIA · 4 files in common
- ESPP European Sustainable Phosphorus Platform · 4 files in common
- IDEE ECONOMICHE www.idee-economiche.it · 3 files in common
Showing 5 of 170.
Is this your organization?
Everything on this page comes from Sanofi’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.